Search Results

Adicet Bio, Inc. today announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Healthcare Conference being held from June 5-6, 2024 in New York.

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced it granted inducement awards on June 28, 2024.

Adicet Bio, Inc. today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to ADI-001 for the potential treatment of relapsed/refractory class III or class IV lupus nephritis.

Adicet Bio, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application to evaluate ADI-270, an armored allogeneic “off-the-shelf” gamma delta chimeric antigen receptor (CAR) T cell therapy candidate targeting CD70+ cancers, for the treatment of relapsed/refractory renal cell carcinoma (RCC).

Adicet Bio, Inc., a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, announced it granted inducement awards on May 31, 2024.

Adicet Bio, Inc. announced that Chen Schor, President and Chief Executive Officer, will participate in a fireside chat at the 2024 Citizens JMP Life Sciences Conference being held from May 13-14, 2024 in New York.

Adicet Bio, Inc. announced the acceptance of a poster presentation at the upcoming European Hematology Association Hybrid Congress being held in Madrid, Spain from June 13-16, 2024.